Exceptional Young Scientists Awarded Scholarships and Awards at the 63rd Annual National Junior Science and Humanities Symposium
CHANTILLY, Va.--(BUSINESS WIRE)--Apr 28, 2025--
Junior Science and Humanities Symposium (JSHS), the nation's premier showcase for high school science, technology, engineering, and math (STEM) research, proudly announces the 2025 winners of the 63 rd National JSHS competition.
JSHS is sponsored by the Department of Defense (DoD) and administered by the National Science Teaching Association. This year's National JSHS event took place April 22-26 at the Westfields Marriott Washington Dulles in Chantilly, Virginia. The event welcomed 239 of the brightest high school STEM students from across the country, their teachers, and JSHS university partners. Esteemed judging panels of scientists from the Department of Defense selected the top presenters in each of the eight categories.
'Each year, the students at JSHS redefine the possibilities in STEM,' said Winnie Boyle, Senior Director of Competitions, NSTA. 'Their groundbreaking research and unwavering curiosity inspire us all, and we are honored to support their academic journeys with scholarships and awards.'
The National JSHS competition awarded 48 national winners, selected from students who first presented their original research at one of 49 regional symposia held at universities and colleges across the U.S., Puerto Rico, and DoDEA schools worldwide. The top five students from each region were invited to compete at the National JSHS event as national finalists. Of these five, the top two finalists competed in oral presentations for the chance to win scholarships ranging from $4,000-$12,000 and the remaining three finalists competed in the poster competition for a chance to win cash awards. In total, the National JSHS event awarded $192,000 in scholarships and $10,800 in cash awards to the national winners.
'JSHS is a testament to the creativity and determination of young researchers nationwide. It is an honor to celebrate these bright young minds as they push the boundaries of scientific discovery and innovation. Congratulations to this year's national winners, whose hard work and passion for research are commendable. We look forward to seeing the impact they will have on the future of science and technology,' said NSTA Interim Chief Executive Officer Bob Lay.
Abstract submissions for the 2024-2025 JSHS competition will open in the fall. For more information on JSHS, visit www.jshs.org.
1 st Place Oral Presentations: earning $12,000 scholarships
Vocalyze: A Deep Learning Approach to Detecting Major Depressive Disorder (MDD) and Tracking Treatment Efficacy via Vocal Acoustic Inflections and Sentiment Analysis
Multi-Color Magneto-Fluorescent Nanoarchitectures for the Targeted Identification of Exosomes of Triple Negative Breast Cancer
Physics-Informed Machine Learning for Many-Objective Generative Design
BeeMind AI: Development of an Artificial Intelligence-Based System to Assess Honeybee Health, Behavior, and Nutrient Effects
Turf Trouble: Does The DEET In Bug Repellent Really Kill Grass? Year II
AI on Edge: Novel Post-Training Quantization for Education Applications
ParkinSense: A Telehealth Toolkit for Quantitative Analysis of Motor Symptoms in Parkinson's Disease
Revolutionizing Turbulence Studies: Novel Low-Cost Zero Mean-Flow Chamber Design and Physics-Informed Tensor Basis Neural Network
2 nd Place Oral Presentations: earning $8,000 scholarships
Characterizing the RyR2-Mediated Cardiac Pathophysiology of COVID-19 in Rodent Models
ICEFAB-Nano: An Integrated Computational-Experimental Framework to Accelerate the Development of Highly Biofunctional Nanotherapeutics for Healthy and Cancerous Applications
Next-Generation VTOL Drones: A Breakthrough in Tilt Mechanism and Modular Design for Optimization and Accessibility
Investigating the Influence of Coal Ash Heavy Metal Leachate on Thyroid Hormone Concentration, Hormone Receptor Gene Expression, and Spectral Sensitivity in Danio Rerio
The Neurobiology of Voluntary Exercise: A Novel Approach to Alleviate Chemobrain by Promoting Hippocampal Neurogenesis
Multi-Branch Temporal-Spectral LSTM-CNN in Deepfake Audio Detection
Early Detection of Critical Salmonella Cases for Pre-Emptive Treatment via Novel Biomarkers discovered through Protein Domain Analysis and Machine Learning
A Novel Method to Analyze Thermonuclear Explosions in Four Binary Star Systems Using NASA's High Time Resolution TESS Data
3 rd Place Oral Presentations: earning $4,000 scholarships
Decoding ASXL3: A Novel Biomarker and Treatment for Neurodevelopmental Disorders
Combating Alzheimer's Disease: Design and Synthesis of a Novel Drug Molecule for Targeted Metal Chelation Therapy
Mitigation of Pressure Injuries: Inertial Wearable and Computer Vision Approaches
A Novel Method of Water Purification: Optimizing Foam Fractionation for Effective Broad-Spectrum Removal of DBP and DBP Precursors in Chlorinated Drinking Water
Effects of Epigallocatechin Gallate (EGCG) and Piperine Compounds on the Regeneration of D. Tigrina
Identifying Key Factors to Improve Autism Spectrum Disorder Diagnosis with Machine LearningWater World Exoplanet Atmospheric and Spectral Data Analysis via Thermodynamic Modeling and Unsupervised Machine Learning
1 st Place Poster Presentations
2 nd Place Poster Presentations
3 rd Place Poster Presentations
View source version on businesswire.com:https://www.businesswire.com/news/home/20250428735527/en/
CONTACT: Winnie S. Boyle
703.312.0387
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA VIRGINIA
INDUSTRY KEYWORD: SCIENCE PUBLIC POLICY/GOVERNMENT OTHER SCIENCE DEFENSE WHITE HOUSE/FEDERAL GOVERNMENT OTHER DEFENSE PRIMARY/SECONDARY EDUCATION
SOURCE: National Science Teaching Association
Copyright Business Wire 2025.
PUB: 04/28/2025 09:15 AM/DISC: 04/28/2025 09:14 AM
http://www.businesswire.com/news/home/20250428735527/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 hours ago
- Business Wire
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. 'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.' 'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.' About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit
Yahoo
2 days ago
- Yahoo
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 06, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and thereafter in equal portions upon the lapse of each three-month period over the following 36-month period, subject to the employee's continued employment with Neurogene through the applicable vesting dates. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit View source version on Contacts Company Contact: Cara MayfieldVice President, Corporate Investor Contact: Melissa ForstArgot PartnersNeurogene@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
